

Resource Summary Report

Generated by [dkNET](#) on Aug 30, 2026

ERK 2 (D-2)

RRID:AB_627547

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-1647, RRID:AB_627547

Antibody Information

URL: http://antibodyregistry.org/AB_627547

Proper Citation: Santa Cruz Biotechnology Cat# sc-1647, RRID:AB_627547

Target Antigen: ERK 2 (D-2)

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: Immunohistochemistry; ELISA; Western Blot; Flow Cytometry; Immunocytochemistry; Immunoprecipitation; Immunofluorescence; IF, IHC

Antibody Name: ERK 2 (D-2)

Description: This monoclonal targets ERK 2 (D-2)

Target Organism: rat, mouse, human

Antibody ID: AB_627547

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-1647

Record Creation Time: 20250819T234940+0000

Record Last Update: 20250820T063232+0000

Ratings and Alerts

No rating or validation information has been found for ERK 2 (D-2).

No alerts have been found for ERK 2 (D-2).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. *Nature communications*, 17(1).

Chattergoon NN, et al. (2026) B-Raf is required for normal murine cardiac development and function. *American journal of physiology. Regulatory, integrative and comparative physiology*, 330(6), R590.

Ojea Ramos S, et al. (2026) Hippocampal ERK2 dimerization regulates inhibitory avoidance memory reconsolidation and synaptic plasticity. *iScience*, 29(7), 116649.

Biancur DE, et al. (2026) Iron overload suppresses LKB1 and induces IL36G anti-tumor immunity in PDAC metastasis. *Science advances*, 12(29), eadz8681.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. *Cell*, 189(6), 1731.

Tan T, et al. (2025) Revisiting phosphoregulation of Cdc25C during M-phase induction. *iScience*, 28(1), 111603.

Doro Pereira L, et al. (2025) PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. *Cancer research communications*, 5(2), 339.

Dias D, et al. (2025) MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma. *Cell reports*, 44(12), 116499.

Pivonello C, et al. (2025) miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects. *Endocrinology*, 166(8).

Biber P, et al. (2025) USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilization. *Cell reports*, 44(10), 116372.

Bongiovanni C, et al. (2024) BMP7 promotes cardiomyocyte regeneration in zebrafish and adult mice. *Cell reports*, 43(5), 114162.

Dias D, et al. (2024) Functional specialization of MITF, TFEB and TFE3 drives radically distinct adaptive gene expression programs in melanoma. *bioRxiv : the preprint server for biology*.

Wang X, et al. (2023) Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. *Cell reports*, 42(1), 111972.

Auf der Maur P, et al. (2023) N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K γ inhibition in breast cancer. *Cell reports. Medicine*, 4(4), 101002.

Xu C, et al. (2023) The Agonist of Adenosine A1 Receptor Induced Desensitization of delta Opioid receptor-mediated Raf-1/MEK/ERK Signaling by Feedback Phosphorylation of Raf-1-Ser289/296/301. *Neurochemical research*, 48(5), 1531.

Iyer SR, et al. (2023) Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. *EMBO molecular medicine*, 15(10), e17367.

Lapadula D, et al. (2023) IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression. *Molecular cancer therapeutics*, 22(1), 63.

Zhang J, et al. (2023) A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. *Molecular cell*, 83(15), 2692.

Martinez-Turtos A, et al. (2022) IRE1 γ overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response. *Oncoimmunology*, 11(1), 2116844.

Grima-Reyes M, et al. (2022) Tumoral microenvironment prevents de novo asparagine biosynthesis in B cell lymphoma, regardless of ASNS expression. *Science advances*, 8(27), eabn6491.